Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$17.41 - $30.05 $327,308 - $564,940
18,800 New
18,800 $530,000
Q2 2022

Aug 12, 2022

SELL
$17.91 - $52.25 $588,253 - $1.72 Million
-32,845 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$66.92 - $84.79 $525,991 - $666,449
-7,860 Reduced 19.31%
32,845 $2.75 Million
Q3 2021

Nov 10, 2021

BUY
$46.83 - $73.5 $1.04 Million - $1.63 Million
22,200 Added 119.97%
40,705 $2.71 Million
Q1 2021

May 13, 2021

SELL
$35.69 - $52.72 $301,580 - $445,484
-8,450 Reduced 31.35%
18,505 $803,000
Q3 2020

Nov 13, 2020

BUY
$27.03 - $47.97 $728,593 - $1.29 Million
26,955 New
26,955 $881,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.